國立虎尾科技大學 |

Lasso Peptides = Bacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Lasso Peptides/ by Yanyan Li, Séverine Zirah, Sylvie Rebuffat.
Reminder of title:	Bacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds /
Author:	Li, Yanyan.
other author:	Zirah, Séverine.
Description:	XIII, 103 p. 22 illus., 9 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Medical microbiology. -
Online resource:	https://doi.org/10.1007/978-1-4939-1010-6
ISBN:	9781493910106

Lasso Peptides = Bacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds /
Li, Yanyan.

Lasso PeptidesBacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds /[electronic resource] :by Yanyan Li, Séverine Zirah, Sylvie Rebuffat. - 1st ed. 2015. - XIII, 103 p. 22 illus., 9 illus. in color.online resource. - SpringerBriefs in Microbiology,2191-5385. - SpringerBriefs in Microbiology,.

Overview on Lasso Peptide Research -- From the Producer Microorganisms to the Lasso Scaffold -- Biological Activities of Lasso Peptides and Structure-Activity Relationships -- Biosynthesis, Regulation and Export of Lasso Peptides -- Lasso Peptide Bioengineering and Bioprospecting.

Lasso peptides form a growing family of fascinating ribosomally-synthesized and post-translationally modified peptides produced by bacteria. They contain 15 to 24 residues and share a unique interlocked topology that involves an N-terminal 7 to 9-residue macrolactam ring where the C-terminal tail is threaded and irreversibly trapped. The ring results from the condensation of the N-terminal amino group with a side-chain carboxylate of a glutamate at position 8 or 9, or an aspartate at position 7, 8 or 9. The trapping of the tail involves bulky amino acids located in the tail below and above the ring and/or disulfide bridges connecting the ring and the tail. Lasso peptides are subdivided into three subtypes depending on the absence (class II) or presence of one (class III) or two (class I) disulfide bridges. The lasso topology results in highly compact structures that give to lasso peptides an extraordinary stability towards both protease degradation and denaturing conditions. Lasso peptides are generally receptor antagonists, enzyme inhibitors and/or antibacterial or antiviral (anti-HIV) agents. The lasso scaffold and the associated biological activities shown by lasso peptides on different key targets make them promising molecules with high therapeutic potential. Their application in drug design has been exemplified by the development of an integrin antagonist based on a lasso peptide scaffold. The biosynthesis machinery of lasso peptides is therefore of high biotechnological interest, especially since such highly compact and stable structures have to date revealed inaccessible by peptide synthesis. Lasso peptides are produced from a linear precursor LasA, which undergoes a maturation process involving several steps, in particular cleavage of the leader peptide and cyclization. The post-translational modifications are ensured by a dedicated enzymatic machinery, which is composed of an ATP-dependent cysteine protease (LasB) and a lactam synthetase (LasC) that form an enzymatic complex called lasso synthetase. Microcin J25, produced by Escherichia coli AY25, is the archetype of lasso peptides and the most extensively studied. To date only around forty lasso peptides have been isolated, but genome mining approaches have revealed that they are widely distributed among Proteobacteria and Actinobacteria, particularly in Streptomyces, making available a rich resource of novel lasso peptides and enzyme machineries towards lasso topologies.

ISBN: 9781493910106

Standard No.: 10.1007/978-1-4939-1010-6doiSubjects--Topical Terms:

583124
Medical microbiology.

LC Class. No.: QR46

Dewey Class. No.: 616.9041

Lasso Peptides = Bacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds /
LDR:04188nam a22003975i 4500 001 966242
003 DE-He213
005 20200630020701.0
007 cr nn 008mamaa
008 201211s2015 xxu| s |||| 0|eng d
020 $a 9781493910106 $9 978-1-4939-1010-6
024 7 $a 10.1007/978-1-4939-1010-6 $2 doi
035 $a 978-1-4939-1010-6
050 4 $a QR46
072 7 $a MMFM $2 bicssc
072 7 $a MED052000 $2 bisacsh
072 7 $a MKFM $2 thema
082 0 4 $a 616.9041 $2 23
100 1 $a Li, Yanyan. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1062894
245 1 0 $a Lasso Peptides $h [electronic resource] : $b Bacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds / $c by Yanyan Li, Séverine Zirah, Sylvie Rebuffat.
250 $a 1st ed. 2015.
264 1 $a New York, NY : $b Springer New York : $b Imprint: Springer, $c 2015.
300 $a XIII, 103 p. 22 illus., 9 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a SpringerBriefs in Microbiology, $x 2191-5385
505 0 $a Overview on Lasso Peptide Research -- From the Producer Microorganisms to the Lasso Scaffold -- Biological Activities of Lasso Peptides and Structure-Activity Relationships -- Biosynthesis, Regulation and Export of Lasso Peptides -- Lasso Peptide Bioengineering and Bioprospecting.
520 $a Lasso peptides form a growing family of fascinating ribosomally-synthesized and post-translationally modified peptides produced by bacteria. They contain 15 to 24 residues and share a unique interlocked topology that involves an N-terminal 7 to 9-residue macrolactam ring where the C-terminal tail is threaded and irreversibly trapped. The ring results from the condensation of the N-terminal amino group with a side-chain carboxylate of a glutamate at position 8 or 9, or an aspartate at position 7, 8 or 9. The trapping of the tail involves bulky amino acids located in the tail below and above the ring and/or disulfide bridges connecting the ring and the tail. Lasso peptides are subdivided into three subtypes depending on the absence (class II) or presence of one (class III) or two (class I) disulfide bridges. The lasso topology results in highly compact structures that give to lasso peptides an extraordinary stability towards both protease degradation and denaturing conditions. Lasso peptides are generally receptor antagonists, enzyme inhibitors and/or antibacterial or antiviral (anti-HIV) agents. The lasso scaffold and the associated biological activities shown by lasso peptides on different key targets make them promising molecules with high therapeutic potential. Their application in drug design has been exemplified by the development of an integrin antagonist based on a lasso peptide scaffold. The biosynthesis machinery of lasso peptides is therefore of high biotechnological interest, especially since such highly compact and stable structures have to date revealed inaccessible by peptide synthesis. Lasso peptides are produced from a linear precursor LasA, which undergoes a maturation process involving several steps, in particular cleavage of the leader peptide and cyclization. The post-translational modifications are ensured by a dedicated enzymatic machinery, which is composed of an ATP-dependent cysteine protease (LasB) and a lactam synthetase (LasC) that form an enzymatic complex called lasso synthetase. Microcin J25, produced by Escherichia coli AY25, is the archetype of lasso peptides and the most extensively studied. To date only around forty lasso peptides have been isolated, but genome mining approaches have revealed that they are widely distributed among Proteobacteria and Actinobacteria, particularly in Streptomyces, making available a rich resource of novel lasso peptides and enzyme machineries towards lasso topologies.
650 0 $a Medical microbiology. $3 583124
650 0 $a Immunology. $3 592892
650 0 $a Vaccines. $3 582184
650 1 4 $a Medical Microbiology. $3 668401
650 2 4 $a Vaccine. $3 782685
700 1 $a Zirah, Séverine. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1261875
700 1 $a Rebuffat, Sylvie. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 785075
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9781493910113
776 0 8 $i Printed edition: $z 9781493910090
830 0 $a SpringerBriefs in Microbiology, $x 2191-5385 $3 1255406
856 4 0 $u https://doi.org/10.1007/978-1-4939-1010-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)